Anzeige
Mehr »
Mittwoch, 29.04.2026 - Börsentäglich über 12.000 News
Zuerst +50%… jetzt ein $20M Graphen-Deal
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DP4W | ISIN: SE0009607252 | Ticker-Symbol: 2E9
Frankfurt
28.04.26 | 08:03
0,062 Euro
-0,49 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INTERVACC AB Chart 1 Jahr
5-Tage-Chart
INTERVACC AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,1080,11107:27

Aktuelle News zur INTERVACC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoIntervacc brings together leading US and European experts to jointly tackle strangles2
INTERVACC Aktie jetzt für 0€ handeln
16.04.Intervacc AB: Unprecedented decision opens the way for the launch of Strangvac in Iceland133Intervacc AB (publ) announces that Strangvac, the company's innovative vaccine against strangles in horses, has been approved by the authorities in Iceland. Strangles, a potentially lethal infection...
► Artikel lesen
14.04.Intervacc publishes the 2025 Annual Report1
10.04.Notice of Annual General Meeting in Intervacc AB (publ)1
19.03.Intervacc AB: Intervacc announces breakthrough protection against Streptococcus suis infection in piglets154Intervacc AB (publ) is first in the world to show that piglets were protected against the virulent and severe disease-causing S. suis Sequence Types 1 and 16 (serotype 2 and 9, respectively), by vaccinating...
► Artikel lesen
09.03.Intervacc presents to the capital market on three occasions in March2
17.02.Intervacc AB Q4 Sales Decline1
17.02.Intervacc AB: Year-end report January - December 2025216The Group in summary 01/10/25 01/10/24 Full year Full year -31/12/25 -31/12/24 2025 2024 Net...
► Artikel lesen
05.02.Intervacc AB: Intervacc announces change of CEO224The Board of Directors of Intervacc AB (publ), together with Jonas Sohlman, has agreed that he will leave his role as Chief Executive Officer and Group CEO. Simultaneously, the Board has appointed...
► Artikel lesen
16.12.25Intervacc AB: Clinical studies with Strangvac have begun in the U.S. market173Intervacc AB (publ) announces that the company has started the first phase of clinical safety studies in horses in the United States as part of the approval process for Strangvac in the U.S. The initial...
► Artikel lesen
19.11.25Intervacc AB: Interim report January - September 2025186The Group in summary 01/07/25 01/07/24 01/01/25 01/01/24 Full year -30/09/25 -30/09/24 -30/09/25 -30/09/24 2024 Net...
► Artikel lesen
13.10.25Intervacc AB: Intervacc and Dechra extend distribution agreement for Intervacc's equine strangles vaccine Strangvac by two years203Intervacc AB (publ) announces today that the five-year distribution agreement signed in April 2021 with its partner Dechra Pharmaceuticals PLC has been extended by two years. The extension will take...
► Artikel lesen
29.08.25Intervacc AB: Interim report January - June 2025260The Group in summary 01/04/25 01/04/24 01/01/25 01/01/24 Full year -30/06/25 -30/06/24 -30/06/25 -30/06/24 2024 Net...
► Artikel lesen
14.05.25Intervacc AB: Interim report January - March 2025261The Group in summary 01/01/25 01/01/24 01/01/24 -31/03/25 -31/03/24 -31/12/24 Net...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1